Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLAT-001 for Lower Eyelid Steatoblepharon
NCT05935527Phase 1Completed
- Sponsor
- Peregrine Ophthalmic
- Start
- Apr 2023
- Primary completion
- Sep 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial in Steatoblepharon comparing Placebo (Normal Saline) with POLAT-001 (2 arms). Primary endpoint: Mean change of photonumeric volume of eyebags. Started Apr 2023; status: completed.
02
Drugs
liposomal latanoprost
03
Conditions
Steatoblepharon
Beyond the preview
Go deeper on NCT05935527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05935527.